10-Q: PAVmed Reports Q3 Loss, Navigates Nasdaq Listing & Funding

PAVmed Inc. reported a net loss for Q3 2025, facing a going concern warning while advancing subsidiary products and addressing Nasdaq compliance through a proposed reverse stock split.

Summary

• PAVmed Inc. reported a net loss attributable to common stockholders of $6.328 million for the three months ended September 30, 2025, compared to a net income of $64.316 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss attributable to common stockholders was $1.942 million, a significant reduction from the $30.620 million net income in the prior year, largely influenced by the deconsolidation of Lucid Diagnostics.
• Revenue for the three months ended September 30, 2025, was minimal at $5 thousand, down from $996 thousand in Q3 2024, primarily due to Lucid Diagnostics' deconsolidation.
• The company had a working capital deficiency of approximately $6.3 million as of September 30, 2025, and ended the quarter with $3.103 million in cash.
• PAVmed's investment in Lucid Diagnostics, now an equity method investment, increased in fair value to $31.615 million as of September 30, 2025, from $25.637 million at December 31, 2024.
• Management fee income from Lucid Diagnostics significantly increased to $3.150 million for Q3 2025 and $9.450 million for the nine months ended September 30, 2025, compared to $700 thousand for the respective periods in 2024.
• The company is addressing a Nasdaq listing compliance issue due to its common stock trading below $1.00 per share and plans to seek shareholder approval for a reverse stock split on December 5, 2025.
• Veris Health, a majority-owned subsidiary, launched the commercial phase of its strategic partnership with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) on October 7, 2025.
• Lucid Diagnostics, an equity method investment, submitted a clinical evidence package to MolDx in November 2024 for Medicare coverage of EsoGuard and received positive coverage policy from Highmark Blue Cross Blue Shield in New York state effective May 26, 2025.
• PAVmed executed a non-binding letter of intent with Duke University on August 26, 2025, to license endoscopic esophageal imaging technology through a newly formed subsidiary.

Sentiment

Score: 3

Explanation: The company faces significant financial distress, including a net loss, minimal revenue for the parent entity, a working capital deficiency, and an explicit going concern warning. While subsidiaries show promising strategic and clinical developments, and capital has been raised, the core financial health of PAVmed Inc. is weak, and the Nasdaq delisting risk is a major concern. The positive developments are largely in subsidiaries, which are now separate entities or majority-owned, not directly reflecting strong performance at the parent level.

Positives

• Cash balance increased to $3.103 million as of September 30, 2025, from $1.185 million at December 31, 2024.
• Total liabilities significantly decreased to $12.282 million as of September 30, 2025, from $37.693 million at December 31, 2024, largely due to the debt exchange.
• Net cash flows used in operating activities substantially improved to $3.655 million for the nine months ended September 30, 2025, compared to $33.648 million in the prior year.
• Management fee income from Lucid Diagnostics saw a significant increase, providing a stable revenue stream for PAVmed.
• Lucid Diagnostics achieved several milestones, including being added to the Russell 2000 and 3000 Indexes, launching a comprehensive testing program with Hoag, and receiving positive coverage from Highmark Blue Cross Blue Shield.
• NCCN Clinical Practice Guidelines updated in March 2025 to reference non-endoscopic biomarker testing like EsoGuard for BE screening, enhancing market acceptance.
• Veris Health launched the commercial phase of its strategic partnership with OSUCCC – James, indicating progress in its Cancer Care Platform.
• PAVmed secured new financing through its ATM facility and a February 2025 offering, providing capital for operations and subsidiary development.
• The company successfully completed a Debt Exchange Agreement in January 2025, significantly reducing its Senior Secured Convertible Notes outstanding.

Negatives

• Reported a net loss attributable to PAVmed Inc. common stockholders of $6.328 million for Q3 2025 and $1.942 million for the nine months ended September 30, 2025.
• Revenue for the parent company remains extremely low at $5 thousand for Q3 2025 and $19 thousand for the nine months ended September 30, 2025, following Lucid's deconsolidation.
• The company has a working capital deficiency of approximately $6.3 million as of September 30, 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern within one year.
• PAVmed's common stock bid price has been below the Nasdaq minimum of $1 per share, leading to a delisting risk, necessitating a proposed reverse stock split.
• The company continues to experience recurring losses and negative cash flows from operating activities.
• Significant dilution occurred through the issuance of common stock for debt conversions and capital raises, including temporary reductions in Series C Preferred Stock conversion price.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to recurring losses, negative cash flows, and working capital deficiency.
• The company's ability to continue operations depends on controlling operating costs, substantially increasing revenues from the Veris Cancer Care platform, and raising additional capital through equity or debt financings.
• Failure to regain compliance with Nasdaq's minimum bid price requirement ($1 per share) by January 19, 2026, could result in delisting of the common stock.
• The company is subject to financial covenants on its September 2022 Senior Convertible Note (minimum $8.0 million available cash, Debt to Market Cap Ratio Test, Market Cap Test of $75 million), although these were waived until December 31, 2025.
• The Series C Preferred Stock has a financial covenant requiring the company to maintain its cash flow on a break-even basis.
• Future financings, acquisitions, mergers, dispositions, joint ventures, or investments may not reflect the potential impact on actual results.
• The risk that the FDA will cease to exercise enforcement discretion with respect to Laboratory Developed Tests (LDTs), like EsoGuard, could impact commercialization.
• Legal proceedings, though currently not deemed material, are subject to inherent uncertainties and could result in material adverse impacts on the company's business, financial position, results of operations, and/or cash flows.

Future Outlook

The company expects to continue experiencing recurring losses and negative cash flows from operating activities in the near future. Its ability to continue operations for the next 12 months depends on controlling operating costs, substantially increasing revenues from the Veris Cancer Care platform, and raising additional capital through various potential sources including equity or debt financings or restructuring existing debt obligations. PAVmed will continue to support the commercial expansion of EsoGuard through Lucid Diagnostics and focus on strategic partnerships for the Veris Cancer Care Platform, while also developing an implantable physiological monitor. The company also plans to explore external innovations and obtain product-by-product financing for its PMX incubator platform. A reverse stock split is planned to address Nasdaq listing requirements.

Management Comments

• Management assesses the company's ability to continue as a going concern for the one year period following the date of the financial statements being issued.
• The company expects to continue to experience recurring losses and to generate negative cash flows from operating activities in the near future.
• The company's ability to continue operations 12 months beyond the issuance of the financial statements, will depend upon its ability to control its operating costs within the limits of the amounts collected from its management service contracts with its non-consolidated subsidiaries, to substantially increase its revenues from the Veris Cancer Care platform, and to raise additional capital through various potential sources.
• We are focused in the immediate term on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Cancer Care Platform, while concurrently developing an implantable physiological monitor.
• We have adopted an incubator-type platform where we are looking to obtain financing on a product-by-product basis as necessary to advance each asset to a meaningful inflection point along its path to commercialization.

Industry Context

PAVmed operates in the highly innovative yet capital-intensive life sciences and medical device industry. The company's strategy of establishing distinct subsidiaries for each financed asset allows for tailored capital raising, a common approach for diversified biotech firms seeking to de-risk individual projects. The focus on early detection of esophageal precancer (EsoGuard) aligns with a growing trend in preventative medicine and personalized diagnostics. The development of the Veris Cancer Care Platform and an implantable physiological monitor taps into the expanding digital health and remote patient monitoring markets, particularly in oncology, which is a high-growth area. The pursuit of strategic partnerships with academic oncology systems is a recognized pathway for clinical validation and market penetration in specialized medical fields. The industry is characterized by significant R&D expenses, regulatory hurdles, and the need for substantial capital, which PAVmed's financial situation reflects.

Comparison to Industry Standards

• The significant decrease in PAVmed's direct revenue post-Lucid deconsolidation highlights the challenge of maintaining a robust top-line for a parent company that spins off its most commercially advanced assets. This contrasts with more mature life science companies that have multiple revenue-generating products under a single entity.
• Lucid Diagnostics' inclusion in the Russell 2000 and 3000 Indexes indicates a level of market recognition and liquidity that is a positive benchmark for a relatively young diagnostic company, suggesting it is performing comparably to other small-cap growth companies in the broader market.
• The positive coverage policies for EsoGuard from Highmark Blue Cross Blue Shield and its reference in NCCN Guidelines are critical for market adoption, aligning with industry standards for securing reimbursement and clinical endorsement, similar to other novel diagnostic tests seeking broad market access.
• The $8 million NIH R01 grant awarded to CWRU/UH for an EsoGuard study in non-GERD patients demonstrates strong external validation and funding for clinical research, comparable to grants received by leading academic institutions for promising medical technologies.
• Veris Health's strategic partnership with OSUCCC – James for its Cancer Care Platform is a standard model for early-stage medical technology companies to gain clinical traction and demonstrate utility within prestigious healthcare systems, similar to partnerships seen with other digital health or oncology-focused startups.
• PAVmed's ongoing need for capital raises and its Nasdaq compliance issues are common for smaller, development-stage life science companies, often reflecting the high burn rates and long development cycles inherent in the sector, which can lead to share price volatility and dilution.

Corporate Governance

Legal Proceedings

• The company is not aware of any pending legal or other proceedings that are reasonably likely to have a material impact on the company.
• Legal proceedings are subject to inherent uncertainties, and an unfavorable outcome could include monetary damages and excessive verdicts, which could result in a material adverse impact on the company's business, financial position, results of operations, and/or cash flows.
• Although the company has specific insurance for certain potential risks, future judgments or settlements of claims may still have a material adverse impact.

Related Party Transactions

• PAVmed records management fee income from Lucid Diagnostics under a Management Services Agreement (MSA). The monthly fee is $1.050 million, totaling $3.150 million for Q3 2025 and $9.450 million for the nine months ended September 30, 2025.
• The September 2022 Senior Convertible Note was amended to require MSA Fees to be paid in cash, and PAVmed is required to set aside 50% of such payments received after January 31, 2025, unless certain conditions are met (MSA Reserve Requirement). This requirement was waived through November 30, 2025.
• PAVmed holds approximately 28% of Lucid Diagnostics' common stock voting interest as of September 30, 2025, and accounts for it as an equity method investment.
• PAVmed holds a 59.49% majority-interest ownership in Veris Health Inc., which is a consolidated majority-owned subsidiary.
• Veris Health owes PAVmed approximately $24.0 million in intercompany debt, convertible into 16,001,294 shares of Veris Health common stock at a stated conversion price of $1.50 per share.

Stakeholder Impact

• **Shareholders**: Face significant dilution from ongoing equity raises and conversions of preferred stock and convertible notes. The proposed reverse stock split aims to maintain Nasdaq listing, which is crucial for liquidity and investor confidence, but does not change underlying value. The going concern warning presents a high risk to equity value.
• **Employees**: Stock-based compensation plans are in place, but the company's financial challenges and potential delisting could impact the perceived value of these awards.
• **Customers (EsoGuard, Veris Cancer Care Platform)**: Benefit from continued product development, expanded access through partnerships (Hoag, OSUCCC – James), and positive coverage policies (Highmark), enhancing the utility and availability of diagnostic and care management tools.
• **Suppliers/Vendors**: The company issued common stock to vendors for services, indicating a reliance on non-cash compensation in some instances, which could affect supplier relationships if not managed carefully.
• **Creditors (Senior Convertible Note holders)**: Have engaged in debt exchanges and granted waivers of financial covenants, indicating a willingness to support the company through its financial challenges, but also reflecting the company's precarious position. The ability to convert debt into Lucid common stock provides an alternative recovery path.

Next Steps

• PAVmed will continue to support the commercial expansion and execution of EsoGuard through its equity method investment, Lucid Diagnostics.
• Veris Health will focus on entering into strategic partnership opportunities with leading academic oncology systems to expand access to the Veris Cancer Care Platform.
• Veris Health will concurrently develop an implantable physiological monitor designed to interface with the Veris Cancer Care Platform.
• PAVmed will seek shareholder approval for an amendment to its Certificate of Incorporation to effect a reverse stock split (1-for-10 to 1-for-30) and an associated reduction in authorized common shares on December 5, 2025.
• PAVmed will continue to explore external innovations that fulfill its project selection criteria without limiting itself to any target sector, specialty or condition, as resources permit.
• PAVmed will look to obtain financing on a product-by-product basis for its PMX incubator-type platform.
• The company will need to control its operating costs and substantially increase revenues from the Veris Cancer Care platform to address its going concern issues.
• PAVmed will continue efforts to raise additional capital through various potential sources including equity or debt financings or refinancing or restructuring existing debt obligations.

Key Dates

Recommendation

PAVmed Inc. presents a high-risk, high-reward scenario. The company's core financial statements show significant losses, minimal revenue for the parent entity, a working capital deficiency, and an explicit 'going concern' warning, which would typically warrant a 'sell' recommendation. However, the company has actively managed its debt, significantly reducing liabilities through exchanges, and has successfully raised capital for itself and its subsidiaries. Furthermore, its key subsidiaries, Lucid Diagnostics and Veris Health, are making substantial strategic and clinical progress, including positive coverage decisions, major partnerships, and significant grant funding. The proposed reverse stock split aims to resolve the Nasdaq listing issue, which is crucial for maintaining investor access and liquidity. For a seasoned investor, the strategic progress and active management of financial challenges, despite the severe risks, might justify a 'hold' position for those willing to tolerate high volatility and speculative potential, betting on the long-term success of the underlying technologies. This is not a recommendation for risk-averse investors.

Keywords

Life Sciences, Medical Devices, Diagnostics, EsoGuard, EsoCheck, Barrett's Esophagus, Esophageal Cancer, Veris Health, Cancer Care Platform, Implantable Physiological Monitor, SEC Filing, 10-Q, Nasdaq Compliance, Reverse Stock Split, Convertible Debt, Equity Financing, Going Concern